Subscribe To
Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress
First patient dosed in pivotal Phase 3 FIREFLY-2/LOGGIC trial evaluating tovorafenib (DAY101) as a frontline therapy for patients newly diagnosed with pediatric low-grade glioma (pLGG) Reported topline data in January 2023 from ongoing, pivotal Phase 2 FIREFLY-1 trial demonstrating meaningful responses with tovorafenib (DAY101) in relapsed or progressive pLGG Additional data from FIREFLY-1 planned for […] The post Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate...
Read More
Posted: Mar 6 2023, 21:30
Author Name: forextv
Views: 101977